ArticleGynecologic oncology2023
Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement.
Article in Gynecologic oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.Advances in therapy · 2026Article
- Impact of cancer during reproductive age on the probability of livebirth after cancer: a register-based cohort study among Danish women aged 18-39 with and without cancer.Journal of cancer survivorship : research and practice · 2026Article
- Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.Journal of gynecologic oncology · 2026Article
- Cervical cancer in the modern era: cutting-edge strategies for diagnosis and treatment.Japanese journal of radiology · 2026Review
- Treatment delay and prolongation in locally advanced cervical cancer.Gynecologic oncology reports · 2026Article
- Mitochondrial HMGCS1 mediates cisplatin resistance in cervical cancer through regulation of mitochondrial transcription.BMC molecular and cell biology · 2026Article
- Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology.American journal of obstetrics and gynecology · 2025Article
- Thieno[2,3-International journal of molecular sciences · 2025Article
- Novel combination of immunotherapy and tyrosine kinase inhibitor for recurrent cervical cancer: balancing efficacy and toxicity.Gynecology and pelvic medicine · 2025Article
- Immunogenic cell death genes in single-cell and transcriptome analyses perspectives from a prognostic model of cervical cancer.Frontiers in genetics · 2025Article
- Trop2 expression, p16 expression status, and histologic subtype in carcinoma of the uterine cervix.Pathology oncology research : POR · 2025Article
- Ulvan Microneedles Loaded with Photosensitizer 5-aminolevulinic Acid Inhibits Human Cervical Cancer HeLa CellsAnti-cancer agents in medicinal chemistry · 2025Article
- Contemporary Review of Adenocarcinoma of the Cervix.Current treatment options in oncology · 2024Review
- How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
Abstract
Cervical cancer is the most commonly diagnosed gynecologic cancer worldwide. Although the incidence has declined with increased screening and higher uptake of human papillomavirus (HPV) vaccination in high-income countries, this disease remains the second highest cause of cancer mortality among women in low- and middle-income countries. In this clinical practice statement, we describe therapies for cervical cancer by treatment setting, as well as quality of life, financial toxicity, and disparities associated with this disease. In addition to chemotherapy and radiation, therapeutic strategies for cervical cancer include immune checkpoint blockade, antiangiogenics, and antibody-drug conjugates. Optimal treatment for recurrent cervical cancer remains an area of unmet need, necessitating further exploration of rational and innovative treatment approaches, including cell and immune-based therapies. Importantly, development of effective therapies for cervical cancer must incorporate strategies to ensure universal equitable access to HPV vaccination, screening, and treatment. Important consequences of the disease and treatment that impact quality of life must also be addressed. Patients with cervical cancer are at increased risk for financial toxicity, which can lead to downstream detrimental effects on physical, financial, and career outcomes. Underrepresentation of racial and ethnic minorities in gynecologic oncology clinical trials highlights the urgent need for collaborative and focused initiatives to bridge the significant divide and alleviate inequalities in the prevention and treatment of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.